A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration

Eye (Basingstoke)

Volumn 31, Issue 1, 2017, Pages 26-44

  Schmidt Erfurth, U ^a   Klimscha, S ^a   Waldstein, S M ^a   Bogunovic H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AGE RELATED MACULAR DEGENERATION; CENTRAL RETINAL THICKNESS; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUSEN; HUMAN; IMAGE ANALYSIS; OPTIC DISK ANOMALY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT CARE; RETINA DETACHMENT; REVIEW; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; GEOGRAPHIC ATROPHY; MACULAR DEGENERATION; PREDICTIVE VALUE; PROCEDURES; TRENDS;

DISEASE MANAGEMENT; DISEASE PROGRESSION; GEOGRAPHIC ATROPHY; HUMANS; MACULAR DEGENERATION; PREDICTIVE VALUE OF TESTS; RETINAL DRUSEN; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 85044561343     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2016.227     Document Type: Review

References (98)

1. Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, ChewE, Csaky K et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013; 120(4): 844-851.
2. Farsiu S, Chiu SJ, OConnell RV, Folgar FA, Yuan E, Izatt JA et al. Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography. Ophthalmology 2014; 121(1): 162-172.
3. Khanifar AA, Koreishi AF, Izatt JA, Toth CA. Drusen ultrastructure imaging with spectral domain optical coherence tomography in age-related macular degeneration. Ophthalmology 2008; 115(11): 1883-1890.
4. Leuschen JN, Schuman SG, Winter KP, McCall MN, Wong WT, Chew EY et al. Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration. Ophthalmology 2013; 120(1): 140-150.
5. Spaide RF, Curcio CA. Drusen characterization with multimodal imaging. Retina 2010; 30(9): 1441-1454.
6. Suzuki M, Curcio CA, Mullins RF, Spaide RF. Refractile drusen: clinical imaging and candidate histology. Retina 2015; 35(5): 859-865.
7. Schlanitz FG, Baumann B, Kundi M, Sacu S, Baratsits M, Scheschy U et al. Drusen volume development over time and its relevance to the course of age-related macular degeneration. Br J Ophthalmol 2016; e-pub ahead of print 4 April 2016; doi:10.1136/bjophthalmol-2016-308422.
8. Yehoshua Z, Wang F, Rosenfeld PJ, Penha FM, Feuer WJ, Gregori G. Natural history of drusen morphology in agerelated macular degeneration using spectral domain optical coherence tomography. Ophthalmology 2011; 118(12): 2434-2441.
9. Querques G, Souied EH. Vascularized drusen: slowly progressive type 1 neovascularization mimicking drusenoid retinal pigment epithelium elevation. Retina 2015; 35(12): 2433-2439.
10. Querques G, Srour M, Massamba N, Georges A, BenMoussa N, Rafaeli O et al. Functional characterization and multimodal imaging of treatment-naive quiescent choroidal neovascularization. Invest Ophthalmol Vis Sci 2013; 54(10): 6886-6892.
11. Roisman L, Zhang Q, Wang RK, Gregori G, Zhang A, Chen CL et al. Optical coherence tomography angiography of asymptomatic neovascularization in intermediate age-related macular degeneration. Ophthalmology 2016; 123(6): 1309-1319.
12. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology 2010; 117(2): 303-12 e1.
13. Zarubina AV, Neely DC, Clark ME, Huisingh CE, Samuels BC, Zhang Y et al. Prevalence of subretinal drusenoid deposits in older persons with and without age-related macular degeneration, by multimodal imaging. Ophthalmology 2016; 123(5): 1090-1100.
14. Saade C, Smith RT. Reticular macular lesions: A review of the phenotypic hallmarks and their clinical significance. Clin Exp Ophthalmol 2014; 42(9): 865-874.
15. Schaal KB, Legarreta AD, Gregori G, Legarreta JE, Cheng Q, Stetson PF et al. Widefield en face optical coherence tomography imaging of subretinal drusenoid deposits. Ophthalmic Surg Lasers Imaging Retina 2015; 46(5): 550-559.
16. Schlanitz F, Baratsits M, Eibenberger K, Montuoro A, Zotter S, Baumann B et al. Investigating the Development of Pseudodrusen in Age-related Macular Degeneration. ARVO Annual Meeting 3-7 May 2015; ARVO: Denver, CO, USA.
17. Querques G, Canoui-Poitrine F, Coscas F, Massamba N, Querques L, Mimoun G et al. Analysis of progression of reticular pseudodrusen by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci 2012; 53(3): 1264-1270.
18. Christenbury JG, Folgar FA, OConnell RV, Chiu SJ, Farsiu S, Toth CA et al. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology 2013; 120(5): 1038-1045.
19. Folgar FA, Yuan EL, Sevilla MB, Chiu SJ, Farsiu S, Chew EY et al. Drusen volume and retinal pigment epithelium abnormal thinning volume predict 2-year progression of agerelated macular degeneration. Ophthalmology 2016; 123(1): 39-50 e1.
20. Schuman SG, KoreishiAF, Farsiu S, Jung SH, Izatt JA, Toth CA. Photoreceptor layer thinning over drusen in eyes with agerelated macular degeneration imaged in vivo with spectraldomain optical coherence tomography. Ophthalmology 2009; 116(3): 488-96 e2.
21. Ouyang Y, Heussen FM, Hariri A, Keane PA, Sadda SR. Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry agerelated macular degeneration. Ophthalmology 2013; 120(12): 2656-2665.
22. Nathoo NA, Or C, Young M, Chui L, Fallah N, Kirker AW et al. Optical coherence tomography-based measurement of drusen load predicts development of advanced age-related macular degeneration. Am J Ophthalmol 2014; 158(4): 757-61 e1.
23. Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC et al. Optical coherence tomography-defined changes preceding the development of drusen-Associated atrophy in age-related macular degeneration. Ophthalmology 2014; 121(12): 2415-2422.
24. Huisingh C, McGwin Jr G, Neely D, Zarubina A, Clark M, Zhang Y et al. The association between subretinal drusenoid deposits in older adults in normal macular health and incident age-related macular degeneration. Invest Ophthalmol Vis Sci 2016; 57(2): 739-745.
25. Spaide RF. Outer retinal atrophy after regression of subretinal drusenoid deposits as a newly recognized form of late age-related macular degeneration. Retina 2013; 33(9): 1800-1808.
26. Schaal KB, Rosenfeld PJ, Gregori G, Yehoshua Z, Feuer WJ, Anatomic Clinical Trial. Endpoints for nonexudative agerelated macular degeneration. Ophthalmology 2016; 123(5): 1060-1079.
27. Jain N, Farsiu S, Khanifar AA, Bearelly S, Smith RT, Izatt JA et al. Quantitative comparison of drusen segmented on SDOCT vs drusen delineated on color fundus photographs. Invest Ophthalmol Vis Sci 2010; 51(10): 4875-4883.
28. Gregori G, Wang F, Rosenfeld PJ, Yehoshua Z, Gregori NZ, Lujan BJ et al. Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. Ophthalmology 2011; 118(7): 1373-1379.
29. Abdelfattah NS, Zhang H, Boyer DS, Rosenfeld PJ, Feuer WJ, Gregori G et al. Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye. Invest Ophthalmol Vis Sci 2016; 57(4): 1839-1846.
30. Chiu SJ, Izatt JA, OConnell RV, Winter KP, Toth CA, Farsiu S. Validated automatic segmentation of AMD pathology including drusen and geographic atrophy in SD-OCT images. Invest Ophthalmol Vis Sci 2012; 53(1): 53-61.
31. deSisternes L, Simon N, Tibshirani R, Leng T, Rubin DL. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. Invest Ophthalmol Vis Sci 2014; 55(11): 7093-7103.
32. Schlanitz FG, Sacu S, Baumann B, BolzM, PlatzerM, Pircher M et al. Identification of drusen characteristics in age-related macular degeneration by polarization-sensitive optical coherence tomography. Am J Ophthalmol 2015; 160(2): 335-44 e1.
33. Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol 2012; 57(5): 389-414.
34. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014; 98(9): 1144-1167.
35. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 2016; 50: 1-24.
36. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010; 30(9): 1333-1349.
37. Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in agerelated macular degeneration. Am J Ophthalmol 2009; 147(4): 644-652.
38. Sato T, Iida T, Hagimura N, Kishi S. Correlation of optical coherence tomography with angiography in retinal pigment epithelial detachment associated with age-related macular degeneration. Retina 2004; 24(6): 910-914.
39. Kuehlewein L, Bansal M, Lenis TL, Iafe NA, Sadda SR, Bonini Filho MA et al. Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Am J Ophthalmol 2015; 160(4): 739-48 e2.
40. Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 2015; 122(4): 822-832.
41. Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I et al. Morphologic parameters relevant for visual outcome during anti-Angiogenic therapy of neovascular agerelated macular degeneration. Ophthalmology 2014; 121(6): 1237-1245.
42. Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I. Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am J Ophthalmol 2015; 160(4): 732-8 e2.
43. Querques G, Atmani K, Berboucha E, Martinelli D, Coscas G, Soubrane G et al. Angiographic analysis of retinal-choroidal anastomosis by confocal scanning laser ophthalmoscopy technology and corresponding (eye-Tracked) spectraldomain optical coherence tomography. Retina 2010; 30(2): 222-234.
44. Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV et al. Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 2015; 35(4): 638-647.
45. Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014; 121(1): 150-161.
46. Kuehlewein L, Dansingani KK, de Carlo TE, Bonini Filho MA, Iafe NA, Lenis TL et al. Optical coherence tomography angiography of type 3 neovascularization secondary to agerelated macular degeneration. Retina 2015; 35(11): 2229-2235.
47. Roberts P, Sugita M, Deak G, Baumann B, Zotter S, Pircher M et al. Automated identification and quantification of subretinal fibrosis in neovascular age-related macular degeneration using polarization-sensitive OCT. Invest Ophthalmol Vis Sci 2016; 57(4): 1699-1705.
48. Shah VP, Shah SA, Mrejen S, Freund KB. Subretinal hyperreflective exudation associated with neovascular agerelated macular degeneration. Retina 2014; 34(7): 1281-1288.
49. Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2015; 122(9): 1846-53 e5.
50. Dansingani KK, Tan A, Gilani F, Phasukkijwatana N, Novais E, Querques L et al. Subretinal hyperreflective material imaged with optical coherence tomography angiography. Am J Ophthalmol 2016; 169: 235-248.
51. Abri Aghdam K, Pielen A, Framme C, Junker B. Correlation between hyperreflective foci and clinical outcomes in neovascular age-related macular degeneration after switching to aflibercept. Invest Ophthalmol Vis Sci 2015; 56(11): 6448-6455.
52. Akagi-Kurashige Y, Tsujikawa A, Oishi A, Ooto S, Yamashiro K, Tamura H et al. Relationship between retinal morphological findings and visual function in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012; 250(8): 1129-1136.
53. Lee H, Ji B, Chung H, Kim HC. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after anti-Vegf treatment in neovascular agerelated macular degeneration and polypoidal choroidal vasculopathy. Retina 2016; 36(3): 465-475.
54. Segal O, Barayev E, Nemet AY, Geffen N, Vainer I, Mimouni M. Prognostic value of hyperreflective foci in neovascular agerelated macular degeneration treated with bevacizumab. Retina 2016; 36(11): 2175-2182.
55. Ritter M, Simader C, Bolz M, Deak GG, Mayr-Sponer U, Sayegh R et al. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol 2014; 98(12): 1629-1635.
56. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013; 120(9): 1860-1870.
57. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2016; 123(4): 865-875.
58. Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS et al. Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration. JAMA Ophthalmol 2016; 134(2): 182-190.
59. Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology 2016; 123(1): 60-69.
60. Gianniou C, Dirani A, Jang L, Mantel I. Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intavitreal ranibizumab: functional and structural outcome. Retina 2015; 35(6): 1195-1201.
61. Penha FM, GregoriG, Garcia Filho CA, Yehoshua Z, FeuerWJ, Rosenfeld PJ. Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy. Retina 2013; 33(3): 459-466.
62. Or C, Chui L, Fallah N, Forooghian F. Volumetric assessment of the responsiveness of pigment epithelial detachments in neovascular age-related macular degeneration to intravitreal bevacizumab. Retina 2016; 36(2): 264-271.
63. Nagiel A, Freund KB, Spaide RF, Munch IC, Larsen M, Sarraf D. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography. Am J Ophthalmol 2013; 156(5): 981-8 e2.
64. Sarraf D, Chan C, Rahimy E, Abraham P. Prospective evaluation of the incidence and risk factors for the development of RPE tears after high-And low-dose ranibizumab therapy. Retina 2013; 33(8): 1551-1557.
65. Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular agerelated macular degeneration in the VIEW trials. Ophthalmology 2016; 123(7): 1521-1529.
66. Sulzbacher F, Roberts P, Munk MR, Kaider A, Kroh ME, Sacu S et al. Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. Invest Ophthalmol Vis Sci 2015; 56(2): 1158-1167.
67. Mayr-Sponer U, Waldstein SM, Kundi M, Ritter M, Golbaz I, Heiling U et al. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology 2013; 120(12): 2620-2629.
68. Waldstein SM, Ritter M, Simader C, Mayr-Sponer U, Kundi M, Schmidt-Erfurth U. Impact of vitreomacular adhesion on ranibizumab mono-And combination therapy for neovascular age-related macular degeneration. Am J Ophthalmol 2014; 158(2): 328-36 e1.
69. Takahashi H, Nomura Y, Tan X, Fujino Y, Kawashima H, Yanagi Y. Effects of posterior vitreous detachment on aqueous humour levels of VEGF and inflammatory cytokines. Br J Ophthalmol 2015; 99(8): 1065-1069.
70. Coscas G, De Benedetto U, Coscas F, Li Calzi CI, Vismara S, Roudot-Thoraval F et al. Hyperreflective dots: A new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013; 229(1): 32-37.
71. Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O et al. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factortreated eyes. Am J Ophthalmol 2015; 159(1): 9-19 e1-2.
72. Xu L, Mrejen S, Jung JJ, Gallego-Pinazo R, Thompson D, Marsiglia M et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular agerelated macular degeneration. Retina 2015; 35(2): 176-186.
73. Abdelfattah NS, Zhang H, Boyer DS, Sadda SR. Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina 2016.
74. Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration-A phase IV randomised clinical trial with ranibizumab: The FLUID study. BMC Ophthalmol 2016; 16: 31.
75. Shi F, Chen X, Zhao H, Zhu W, Xiang D, Gao E et al. Automated 3-D retinal layer segmentation of macular optical coherence tomography images with serous pigment epithelial detachments. IEEE Trans Med Imaging 2015; 34(2): 441-452.
76. Zhang L, Sonka M, Folk JC, Russell SR, Abramoff MD. Quantifying disrupted outer retinal-subretinal layer in SD-OCT images in choroidal neovascularization. Invest Ophthalmol Vis Sci 2014; 55(4): 2329-2335.
77. Xu X, Lee K, Zhang L, Sonka M, Abramoff M. Stratified sampling voxel classification for segmentation of intraretinal and subretinal fluid in longitudinal clinical OCT data. IEEE Trans Med Imaging 2015; 34(7): 1616-1623.
78. Schlegl T, Waldstein SM, Vogl WD, Schmidt-Erfurth U, Langs G. Predicting semantic descriptions from medical images with convolutional neural networks. Inf Process Med Imaging 2015; 24: 437-448.
79. Bogunovic H, Abramoff M, Zhang L, Sonka M. Prediction of Treatment Response from Retinal OCT in Patients with Exudative Age-Related Macular Degeneration. International Workshop on Ophthalmic Medical Image Analysis of MICCAI: Boston, MA, USA, 2014.
80. VoglWD, Waldstein SM, Gerendas BS, Simader C, Glodan AM, Podkowinski D et al. Spatio-Temporal signatures to predict retinal disease recurrence. Inf Process Med Imaging 2015; 24: 152-163.
81. Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Finger RP, Scholl HP et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49(9): 4137-4144.
82. Yehoshua Z, Rosenfeld PJ, Gregori G, Feuer WJ, Falcao M, Lujan BJ et al. Progression of geographic atrophy in agerelated macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011; 118(4): 679-686.
83. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-Valckenberg S. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007; 143(3): 463-472.
84. Fleckenstein M, Schmitz-Valckenberg S, Adrion C, Kramer I, Eter N, Helb HM et al. Tracking progression with spectraldomain optical coherence tomography in geographic atrophy caused by age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51(8): 3846-3852.
85. Simader C, Sayegh RG, Montuoro A, Azhary M, Koth AL, Baratsits M et al. A longitudinal comparison of spectraldomain optical coherence tomography and fundus autofluorescence in geographic atrophy. Am J Ophthalmol 2014; 158(3): 557-66 e1.
86. Schmitz-Valckenberg S, Fleckenstein M, Helb HM, Charbel Issa P, Scholl HP, Holz FG. In vivo imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2009; 50(8): 3915-3921.
87. Bearelly S, Chau FY, Koreishi A, Stinnett SS, Izatt JA, Toth CA. Spectral domain optical coherence tomography imaging of geographic atrophy margins. Ophthalmology 2009; 116(9): 1762-1769.
88. Stetson PF, Yehoshua Z, Garcia Filho CA, Portella Nunes R, Gregori G, Rosenfeld PJ. OCT minimum intensity as a predictor of geographic atrophy enlargement. Invest Ophthalmol Vis Sci 2014; 55(2): 792-800.
89. Moussa K, Lee JY, Stinnett SS, Jaffe GJ. Spectral domain optical coherence tomography-determined morphologic predictors of age-related macular degeneration-Associated geographic atrophy progression. Retina 2013; 33(8): 1590-1599.
90. Hariri AH, Nittala MG, Sadda SR. Quantitative characteristics of spectral-domain optical coherence tomography in corresponding areas of increased autofluorescence at the margin of geographic atrophy in patients with age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2016; 47(6): 523-527.
91. Fleckenstein M, Schmitz-Valckenberg S, Martens C, Kosanetzky S, Brinkmann CK, Hageman GS et al. Fundus autofluorescence and spectral-domain optical coherence tomography characteristics in a rapidly progressing form of geographic atrophy. Invest Ophthalmol Vis Sci 2011; 52(6): 3761-3766.
92. Choi W, Moult EM, Waheed NK, Adhi M, Lee B, Lu CD et al. Ultrahigh-speed, swept-source optical coherence tomography angiography in nonexudative age-related macular degeneration with geographic atrophy. Ophthalmology 2015; 122(12): 2532-2544.
93. Schutze C, Bolz M, Sayegh R, Baumann B, Pircher M, Gotzinger E et al. Lesion size detection in geographic atrophy by polarization-sensitive optical coherence tomography and correlation to conventional imaging techniques. Invest Ophthalmol Vis Sci 2013; 54(1): 739-745.
94. Sayegh RG, Zotter S, Roberts PK, Kandula MM, Sacu S, Kreil DP et al. Polarization-sensitive optical coherence tomography and conventional retinal imaging strategies in assessing foveal integrity in geographic atrophy. Invest Ophthalmol Vis Sci 2015; 56(9): 5246-5255.
95. Niu S, de Sisternes L, Chen Q, Leng T, Rubin DL. Automated geographic atrophy segmentation for SD-OCT images using region-based C-V model via local similarity factor. Biomed Opt Express 2016; 7(2): 581-600.
96. Chen Q, de Sisternes L, Leng T, Zheng L, Kutzscher L, Rubin DL. Semi-Automatic geographic atrophy segmentation for SD-OCT images. Biomed Opt Express 2013; 4(12): 2729-2750.
97. Hu Z, Medioni GG, Hernandez M, Hariri A, Wu X, Sadda SR. Segmentation of the geographic atrophy in spectral-domain optical coherence tomography and fundus autofluorescence images. Invest Ophthalmol Vis Sci 2013; 54(13): 8375-8383.
98. Niu S, de Sisternes L, Chen Q, Rubin DL, Leng T. Fully automated prediction of geographic atrophy growth using quantitative spectral-domain optical coherence tomography biomarkers. Ophthalmology 2016; 123(8): 1737-1750.